plantproduc
vaccin
veterinari
medicin
excit
prospect
larg
possibl
produc
proteinbas
vaccin
includ
edibl
vaccin
low
cost
almost
scale
potenti
local
demand
also
controversi
real
possibl
contamin
human
food
suppli
vaccineproduc
transgen
plant
concern
around
possibl
immunolog
toler
develop
oral
edibl
vaccin
howev
one
set
problem
mani
product
eventu
fact
environ
seem
prime
favour
introduct
main
justif
plantmad
vaccin
vaccin
antigen
product
plant
safe
cheap
highli
scalabl
plant
produc
process
eukaryotederiv
protein
much
better
bacteria
even
yeast
use
plant
would
allow
product
vaccin
develop
world
need
vaccin
therapeut
never
produc
econom
technolog
howev
despit
twenti
year
develop
still
plantproduc
vaccin
biolog
avail
fact
product
licenc
use
human
review
explor
earli
histori
plantproduc
vaccin
emphasi
proof
principl
efficaci
recent
develop
robust
stabl
transient
plant
product
system
vaccin
antigen
could
mean
veterinari
medicin
potenti
plantproduc
vaccin
advanc
anim
potenti
human
health
banner
one
health
movement
viral
protein
probabl
common
vaccin
candid
made
plant
review
rybicki
express
bacteri
coli
heat
labil
enterotoxin
ltb
first
prove
veterinaryrelev
antigen
could
produc
plant
provid
first
proof
principl
edibl
vaccin
ltb
produc
transgen
tobacco
potato
haq
et
al
function
equival
e
coliproduc
protein
specif
assay
immunis
mice
oral
gavag
plant
materi
elicit
system
mucos
toxin
neutralis
antibodi
moreov
fresh
potato
contain
ltb
immunogen
mice
eaten
earli
viru
vaccin
candid
one
mink
enter
viru
mev
diseas
novel
compris
chimaer
cowpea
mosaic
viru
cpmv
virion
incorpor
short
linear
epitop
mev
capsid
protein
display
surfac
virion
produc
inocul
bean
plant
infecti
cdna
clone
rcpmv
dalsgaard
et
al
confer
protect
clinic
diseas
virtual
abolish
viru
given
epitop
sequenc
use
found
mev
canin
parvoviru
felin
panleukopenia
viru
vaccin
could
potenti
also
protect
virus
anoth
earli
viru
vaccin
candid
rabbit
haemorrhag
diseas
viru
rhdv
made
express
whole
rhdv
capsid
protein
transgen
potato
parenter
immunis
plant
extract
protect
rabbit
castanon
et
al
subsequ
anoth
studi
demonstr
edibl
vaccin
consist
leav
transgen
plant
contain
presum
partiallyassembl
subunit
effect
prime
vaccin
later
baculovirusderiv
parenterallydeliv
vaccin
gil
et
al
first
report
foot
mouth
diseas
viru
fmdv
plantmad
antigen
express
plant
protoplast
peptid
fmdv
insert
minor
coat
protein
replic
cpmv
demonstr
antigen
present
usha
et
al
howev
first
proof
efficaci
done
use
transgen
arabidopsi
thaliana
express
whole
parenter
immunis
mice
leaf
extract
elicit
antibodi
bound
intact
fmdv
particl
immunis
mice
protect
virul
fmdv
challeng
carrillo
et
al
wigdorovitz
group
went
demonstr
mice
could
protect
fmdv
challeng
oral
parenter
vaccin
extract
transgen
alfalfa
express
wigdorovitz
et
al
immunis
leaf
extract
tobacco
plant
express
via
recombin
tobacco
mosaic
viru
vector
wigdorovitz
et
al
refin
achiev
includ
transgen
express
alfalfa
amino
acid
residu
fuse
glucuronidas
gu
allow
select
strongest
express
assay
enzym
activ
protect
mice
du
santo
et
al
anoth
novel
applic
carrier
technolog
insert
amino
acid
gh
loop
interior
region
hepat
b
viru
core
antigen
gene
hbcag
express
chimaera
transgen
nicotiana
tabacum
chimaer
protein
form
viruslik
particl
vlp
tobacco
leav
mice
immunis
intraperiton
solubl
extract
protect
viral
challeng
huang
et
al
earli
attempt
show
feasibl
make
anthrax
vaccin
express
transgen
n
tabacum
protect
antigen
pa
protein
bacillu
anthraci
possibl
best
target
subunit
vaccin
alon
protect
aziz
et
al
although
went
show
cytolyt
activ
protein
soon
group
went
express
pa
transplastom
n
tabacum
signific
yield
increas
still
efficaci
trial
aziz
et
al
anoth
investig
transplastom
tobacco
henri
daniel
group
thorough
yield
high
gkg
fresh
leaf
tissu
protein
protect
chloroplast
proteas
cleavag
stabl
store
leav
crude
extract
biolog
activ
watson
et
al
show
immunogen
protect
author
specul
averag
yield
mg
pa
per
plant
use
experiment
transgen
cultivar
grown
greenhous
million
dose
vaccin
free
contamin
could
produc
per
acr
daniel
group
subsequ
show
chloroplastderiv
pa
equal
potenc
natur
product
b
anthraci
mice
immunis
subcutan
partial
purifi
chloroplastderiv
pa
adjuv
produc
high
igg
titr
surviv
challeng
lethal
dose
toxin
koya
et
al
differ
sort
approach
anthrax
one
first
attempt
make
therapeut
antibodi
plant
taken
vidadi
yusibov
group
use
techniqu
transient
agrobacterium
infiltrationmedi
express
n
benthamiana
produc
humanderiv
paspecif
monoclon
antibodi
hull
et
al
antibodi
neutralis
toxin
activ
vitro
vivo
compar
level
hybridomaproduc
antibodi
yusibov
group
becam
fraunhof
usa
center
molecular
biotechnolog
later
use
transient
express
technolog
separ
express
artifici
antigen
compris
domain
pa
domain
b
anthraci
lethal
factor
lf
fuse
infram
lichenas
lickm
thermost
enzym
clostridium
thermocellum
chichest
et
al
mice
immunis
combin
two
antigen
produc
high
titr
mainli
sera
could
neutralis
effect
anthrax
lethal
toxin
letx
vitro
rabi
vaccin
made
plant
includ
earli
yet
highli
sophist
candid
compos
alfalfa
mosaic
viru
amv
cp
fuse
artifici
polypeptid
contain
rabi
viru
g
protein
amino
acid
n
protein
amino
acid
express
either
n
tabacum
plant
transgen
amv
replicas
via
rtmv
either
n
benthamiana
spinach
yusibov
et
al
plant
made
particl
contain
amvderiv
rna
encapsid
chimaer
cp
raw
spinach
leav
oral
immunogen
mice
human
volunt
simpler
candid
g
protein
alon
plant
signal
peptid
er
retent
signal
made
transgen
n
tabacum
ashraf
et
al
yield
rel
low
total
solubl
leaf
protein
purifi
protein
inject
periton
mice
elicit
protect
immun
lethal
intracerebr
challeng
live
rabi
excel
proof
principl
efficaci
plantmad
anim
rotaviru
vaccin
earli
target
standout
studi
yu
langridg
provid
evid
transgen
potato
could
produc
fusion
protein
consist
cholera
toxin
ct
b
subunit
fuse
murin
rotaviru
enterotoxin
enterotoxigen
e
coli
fimbrial
antigen
respect
fusion
antigen
assembl
potato
tuber
cholera
holotoxinlik
structur
bound
enterocyt
elicit
serum
intestin
antibodi
oral
immunis
mice
moreov
passiv
immunis
mous
neonat
partial
protect
diarrhoea
rotaviru
challeng
demonstr
combin
vaccin
viral
bacteri
pathogen
may
made
plant
simpler
approach
rotaviru
prevent
express
histag
fragment
bovin
rotaviru
brv
n
benthamiana
via
recombin
tmv
purif
antigen
chromatographi
intraperiton
immunis
adult
femal
mice
perez
filgueira
et
al
eightyf
percent
suckl
mice
born
mother
protect
brv
challeng
compar
immunis
irrelev
control
antigen
group
also
show
fusion
protein
made
transgen
alfalfa
consist
short
peptid
deriv
brv
fuse
gu
immunogen
given
intraperiton
oral
adult
femal
mice
suckl
protect
challeng
wigdorovitz
et
al
anoth
group
use
transgen
alfalfa
produc
human
rotaviru
show
femal
mice
gavag
alfalfa
extract
contain
oligocpg
adjuv
develop
high
titr
antibodi
system
mucos
pup
partial
protect
simian
rotaviru
challeng
anim
model
first
use
show
efficaci
insect
cellmad
papillomaviru
viruslik
particl
vlp
base
vaccin
breitburd
et
al
also
use
demonstr
efficaci
two
differ
plantmad
papillomaviru
vaccin
year
demonstr
human
papillomaviru
major
capsid
protein
viruslik
particl
could
produc
transgen
tobacco
potato
biemelt
et
al
varsani
et
al
warzecha
et
al
cottontail
rabbit
papillomaviru
crpv
caus
famou
jackalop
sight
usa
provid
excel
model
system
domest
rabbit
investig
prophylact
therapeut
papillomaviru
vaccin
breitburd
et
al
accordingli
first
studi
crpv
major
capsid
proteincontain
extract
prepar
either
transgen
n
tabacum
n
benthamiana
infect
recombin
tmv
use
freund
incomplet
adjuv
immunis
rabbit
subsequ
challeng
live
viru
kohl
et
al
although
vaccin
appear
contain
small
aggreg
crpv
rather
intact
vlp
immun
rabbit
sera
fail
neutralis
crpv
infect
vitro
assay
rabbit
protect
wart
develop
kohl
et
al
second
studi
infecti
recombin
tmv
use
surfac
display
via
fusion
capsid
protein
peptid
consist
amino
acid
minor
capsid
protein
either
crpv
rabbit
oral
papillomaviru
ropv
palmer
et
al
group
rabbit
receiv
either
vaccin
challeng
live
crpv
ropv
immun
rabbit
sera
react
whole
protein
crpvspecif
sera
neutralis
crpv
pseudovirion
infect
rabbit
receiv
crpv
crpv
ropv
vaccin
complet
protect
crpv
infect
receiv
ropv
alon
weakli
protect
crpv
studi
demonstr
first
time
plantmad
papillomaviru
vaccin
base
protein
peptid
real
potenti
prophylact
vaccin
use
anim
well
human
strang
given
bovin
papillomavirus
bpv
use
mani
year
model
system
antiwart
vaccin
transient
agroinfiltrationmedi
express
vlp
n
benthamiana
candid
plantmad
bpv
vlpbase
vaccin
success
made
although
efficaci
trial
done
love
et
al
express
anim
vaccin
compon
seed
transgen
plant
attempt
quit
earli
lamphear
et
al
review
earlier
work
maiz
seed
express
b
subunit
e
coli
heatlabil
enterotoxin
tgev
protein
data
potenc
efficaci
stabil
vaccin
anoth
report
follow
express
maiz
seed
envelop
protein
transmiss
gastroenter
coronaviru
tgev
swine
protect
efficaci
piglet
fed
seed
jilka
follow
earlier
demonstr
oral
immunogen
protein
ntermin
domain
transgen
potato
tuber
gomez
et
al
rabi
target
maiz
seed
express
report
g
protein
express
transgen
maiz
seed
total
solubl
protein
complet
protect
heterolog
rabi
strain
challeng
mice
oral
immun
one
dose
g
protein
seed
extract
lozarubio
et
al
group
later
show
sheep
oral
given
singl
dose
transgen
maiz
seed
contain
mg
g
protein
protect
extent
immun
commerci
inactiv
vaccin
lozarubio
et
al
author
claim
first
studi
oral
administ
edibl
vaccin
show
efficaci
polygastr
model
import
develop
maiz
popular
target
product
storag
recombin
protein
earli
molecular
farm
time
see
streatfield
et
al
howev
host
use
instanc
haemagglutinin
h
protein
rinderpest
viru
express
transgen
pigeon
pea
total
solubl
protein
satyavathi
et
al
also
peanut
product
oral
parenter
immunogen
mice
khandelw
et
al
glycoprotein
b
gb
human
cytomegaloviru
seed
transgen
tobacco
tackaberri
et
al
fusion
f
glycoprotein
newcastl
diseas
viru
transgen
rice
seed
yang
et
al
serotypespecif
protein
bluetongu
viru
transgen
peanut
athmaram
et
al
effort
negat
howev
one
big
scandal
hit
molecular
farm
far
use
food
plant
vaccin
product
concern
aphi
inspector
found
volunt
tgev
cpexpress
maiz
grow
soybean
field
two
locat
use
grow
prodigen
inc
tgev
transgen
maiz
previou
season
aphi
one
soybean
harvest
maiz
plant
still
stand
sent
storag
facil
mix
larg
volum
seed
compani
fine
paid
substanti
cleanup
cost
develop
new
complianc
implement
programm
us
dept
agricultur
issu
new
guidelin
trial
product
unfortun
knockon
effect
molecular
farm
result
effect
voluntari
moratorium
use
food
crop
recombin
protein
product
worldwid
one
major
success
stori
earli
work
veterinari
vaccin
approv
us
depart
agricultur
center
veterinari
biolog
dow
agrosci
inject
newcastl
diseas
viru
ndv
haemagglutinbas
vaccin
poultri
made
suspens
cultur
n
tabacum
cell
line
sadli
product
never
sold
compani
want
demonstr
plantcellproduc
system
capabl
produc
vaccin
safe
effect
demonstr
meet
requir
approv
rigor
usda
regulatori
system
ndv
well
known
understood
regulatori
agenc
serv
excel
model
prove
new
technolog
rybicki
earli
histor
account
molecular
farm
veterinari
vaccin
given
give
idea
array
technolog
avail
use
transgen
transplastom
express
subunit
protein
recombin
plant
virus
either
use
express
whole
vaccin
candid
gene
display
chosen
peptid
fuse
capsid
protein
fusion
vaccin
protein
gene
carrier
protein
improv
immunogen
includ
inher
adjuv
properti
candid
parenter
oral
vaccin
virus
bacteria
therapeut
anim
made
plant
use
plant
cell
cultur
make
antigen
mani
proof
principl
obtain
candid
vaccin
wide
rang
viral
bacteri
diseas
agent
proof
efficaci
vaccin
deliv
oral
parenter
whole
plant
materi
extract
aspect
still
current
use
molecular
farm
develop
revolutionis
field
first
widespread
adopt
agrobacteriummedi
transient
express
agroinfiltr
recombin
protein
second
use
deconstruct
plant
virusderiv
vector
deliv
via
agrobacterium
amplifi
express
review
rybicki
innov
enabl
advent
highthroughput
test
express
construct
coupl
rapid
gener
higher
yield
product
vaccin
antigen
optim
construct
design
determin
exampl
group
investig
via
agroinfiltr
techniqu
three
differ
codon
usag
scheme
three
differ
intracellular
local
strategi
optim
human
papillomaviru
type
protein
express
n
benthamiana
one
larg
experi
day
maclean
et
al
use
deconstruct
tmvbase
vector
deliv
agrobacterium
routin
allow
signific
increas
antigen
yield
gram
per
kilogram
fresh
tissu
weight
gleba
et
al
klimyuk
et
al
socal
tmvbase
launch
vector
fraunhof
usa
also
allow
signific
yield
increas
rapid
product
antigen
chichest
et
al
shamloul
et
al
improv
nonrepl
hypertransl
ht
express
vector
deriv
cowpea
mosaic
viru
also
allow
significantli
higher
yield
via
agroinfiltr
sainsburi
et
al
possibl
multipl
gene
vector
saxena
et
al
use
ssdna
geminivirusderiv
set
vector
differ
group
huang
et
al
regnard
et
al
ssdna
plant
host
virusderiv
vector
rybicki
martin
number
peptid
display
vectorschimaer
protein
fusion
partner
multipli
selfrepl
rtmv
state
art
one
may
choos
tmv
potato
viru
x
pvx
base
vector
lico
et
al
cucumb
mosaic
viru
cmv
cp
nemchinov
natilla
zhao
hammond
bamboo
mosaic
viru
yang
et
al
pvxvector
alternanthera
mosaic
viru
altmv
cp
gene
tyulkina
et
al
lichenas
lickm
cholera
toxin
b
subunit
ctb
amv
cp
gu
mention
earlier
plant
viru
virion
particular
seen
easilymad
nanoparticl
suitabl
number
vaccinerelev
purpos
steel
et
al
includ
selfadjuv
peptidebas
vaccin
display
vehicl
lebel
et
al
leclerc
excel
induc
crosspresent
mhc
receptor
hanafi
et
al
use
tag
small
peptid
fusion
partner
also
consider
sophist
varieti
special
tag
choos
includ
nowubiquit
tag
use
immobilis
metal
affin
chromatographi
imac
protein
purif
techniqu
new
cystatag
purpos
sainsburi
et
al
ntermin
prolinerich
domain
maiz
seed
gamma
zein
zera
induc
format
erloc
protein
bodi
torrent
et
al
elastinlik
polypeptid
elp
repeat
pentapeptid
vpgxg
sequenc
fungal
protein
alter
hydrophob
fusion
also
form
protein
bodi
conley
et
al
exampl
group
recent
success
use
elp
fusion
cp
beak
feather
diseas
viru
bfdv
parrot
aid
accumul
purif
protein
candid
vaccin
duvenag
et
al
also
use
zera
tag
protein
bodi
display
vehicl
ectop
moieti
common
influenzaviru
type
could
serv
univers
vaccin
virus
mbewana
et
al
anoth
potenti
veterinari
use
zera
enhanc
yersinia
pesti
antigen
fusion
protein
accumul
higher
alon
three
differ
host
plant
n
benthamiana
alfalfa
n
tabacum
suspensioncultur
cell
alvarez
et
al
express
vehicl
also
subject
engin
possibl
precis
control
glycosyl
plantmad
protein
done
knockout
modif
via
rna
interfer
rnai
technolog
plant
glycosyltransferas
xylt
core
fuct
enzym
respons
transfer
xylos
core
fucos
residu
glycoprotein
nglycan
plantspecif
modif
found
mammalian
glycoprotein
strasser
et
al
also
possibl
use
transient
coexpress
technolog
modifi
glycosyl
castilho
steinkelln
well
achiev
almost
complet
nativ
sialyl
recombin
protein
express
whole
mammalian
glycosyl
pathway
plant
castilho
et
al
steinkelln
castilho
possibl
abolish
nglycosyl
entir
coexpress
bacteri
pngase
f
mamedov
yusibov
one
also
control
endogen
plant
proteas
may
limit
recombin
protein
accumul
exampl
transient
coexpress
secret
proteas
inhibitor
tomato
cathepsin
inhibitor
slcdi
significantli
lower
proteas
activ
n
benthamiana
apoplast
increas
recombin
protein
content
goulet
et
al
found
coexpress
tomato
cystatin
inhibit
proteas
increas
transient
express
yield
monoclon
antibodi
n
benthamiana
nearli
robert
et
al
also
possibl
reduc
proteas
activ
cell
suspens
cultur
express
specif
antisens
rna
result
significantli
increas
accumul
recombin
antibodi
mandal
et
al
suspensioncultur
plant
cell
use
mani
year
molecular
fact
use
usdalicenc
plantproduc
anim
vaccin
develop
made
even
attract
prospect
lowcost
vaccin
product
use
flow
cytometri
cell
sort
formerli
provinc
mammalian
cell
cultur
work
allow
highexpress
mabproduc
tobacco
cell
line
heterogen
popul
cell
select
coexpress
fluoresc
marker
protein
dsred
kirchhoff
et
al
howev
one
excit
recent
develop
technolog
advent
cell
pack
techniqu
get
highli
effici
agrobacteriummedi
transient
transform
suspensioncultur
cell
captur
suction
onto
filter
rademach
cell
pack
tini
eppendorf
tube
tip
larg
eg
centimetr
deep
cm
buchner
funnel
protein
express
occur
immobilis
cell
presenc
minim
liquid
media
continu
day
http
technolog
ideal
rapid
highthroughput
screen
possibl
exist
take
cell
back
cultur
select
perman
transfect
import
develop
accept
product
plant
cell
cultur
product
biolog
regulatori
bodi
see
anoth
product
host
highli
suit
industrialscal
product
microalga
easier
establish
use
plant
cell
cultur
share
advantag
scalabl
contain
growth
consist
transgen
express
level
specht
mayfield
import
develop
molecular
farm
develop
protocol
increas
yield
implement
industrialscal
product
downstream
process
vaccin
biolog
without
largescal
trial
could
take
place
routin
manufactur
occur
use
develop
use
transgen
n
tabacumn
glauca
hybrid
synthes
alkaloid
highli
vigor
easili
propag
veget
cut
produc
viabl
pollen
greatli
aid
biocontain
ling
et
al
applic
techniqu
familiar
chemic
engin
also
advantag
exampl
prove
possibl
sequenti
use
fraction
factori
design
respons
surfac
methodolog
optim
cultur
media
mab
product
transgen
tobacco
cell
increas
mab
yield
day
cultur
compar
use
standard
media
vasilev
et
al
fraunhof
ime
group
describ
gener
chromatographybas
strategi
focus
bind
behaviour
host
cell
protein
chromatographi
resin
vari
condit
ph
conduct
buyel
fischer
anoth
use
techniqu
group
comprehens
descript
use
heat
treatment
either
intact
leav
plant
extract
facilit
industrialscal
remov
host
cell
protein
optimis
designofexperi
approach
also
familiar
engin
buyel
et
al
mani
strategi
use
optimis
yield
molecular
farm
review
twyman
et
al
establish
variou
compani
institut
facil
suitabl
manufactur
anim
clinic
trial
materi
also
welcom
develop
exampl
longestablish
kentucki
bioprocess
inc
kbp
contract
manufactur
capabl
product
transgen
plant
transient
transfect
plant
use
us
food
drug
administr
current
good
manufactur
practic
cgmp
pharmaceut
scale
thousand
kilogram
plant
per
week
http
wwwkentuckybioprocessingcom
recent
produc
stockpil
mab
ebolavirus
anoth
contract
manufactur
firm
larg
product
capac
ibio
inc
like
kbp
wide
rang
patent
proprietari
gene
express
technolog
holtz
et
al
also
partner
rang
agenc
compani
includ
brazilian
oswaldo
cruz
foundat
plantmad
yellow
fever
vaccin
us
dept
defens
bill
melinda
gate
foundat
influenza
vaccin
http
wwwibioinccom
fraunhof
usa
center
molecular
biotechnolog
http
wwwfhcmborg
notforprofit
research
develop
organis
offer
protein
product
purif
scaleup
gmp
manufactur
support
develop
vaccin
therapeut
diagnost
also
proprietari
express
platform
take
product
right
fill
finish
fraunhof
ime
aachen
also
stateoftheart
mechanis
plant
product
facil
still
construct
regulatori
environ
chang
better
even
though
truth
inim
first
suppos
born
fact
earli
cuban
regulatori
agenc
usda
approv
plantmad
mab
purif
alreadylicenc
yeastmad
hepat
b
vaccin
tobacco
cellmad
ndv
vaccin
respect
rybicki
anoth
earli
exampl
fraunhof
ime
molecular
farm
group
publish
use
whole
plant
biolog
product
lack
intrins
benefit
cell
cultur
techniqu
precis
control
growth
condit
batchtobatch
product
consist
steril
contain
much
harder
complianc
good
manufactur
practic
gmp
hellwig
et
al
point
plant
cell
suspens
cultur
merit
microbi
anim
cell
cultur
establish
track
record
secondari
metabolit
product
far
cheaper
use
justif
notwithstand
group
later
note
review
gmp
issu
plantmad
protein
whole
plant
plantderiv
recombin
protein
intend
medic
fall
regulatori
guidelin
manufactur
cover
drug
sourc
protein
enter
clinic
develop
includ
requir
product
accord
gmp
principl
wellcharacter
gmp
regul
appli
pharmaceut
protein
produc
bacteria
mammalian
cell
directli
transferr
plant
fischer
et
al
subsequ
abl
get
gmp
manufactur
authoris
german
author
make
mab
transgen
n
tabacum
phase
clinic
trial
et
al
entiti
also
scale
regularis
product
allow
product
materi
anim
clinic
one
success
medicago
inc
present
routin
largescal
product
influenzaviru
haemagglutinin
ha
base
vlp
use
advanc
human
clinic
trial
aoust
et
al
medicago
inc
succeed
manufactur
million
dose
vlpbase
influenza
vaccin
candid
one
month
phase
cgmp
part
us
defens
advanc
research
project
agenc
darpa
fund
challeng
darpa
group
japan
also
recent
develop
gmpcompliant
product
process
transgen
rice
seedbas
cholera
simpli
polish
powder
seed
clinic
trial
kashima
et
al
evid
increas
matur
veterinari
molecular
farm
one
editor
book
coauthor
recent
articl
regulatori
commerci
hurdl
hamper
advanc
market
plantproduc
veterinari
vaccin
cover
develop
busi
plan
assess
market
opportun
manufactur
scaleup
financ
protect
use
intellectu
properti
regulatori
approv
macdonald
et
al
first
sight
molecular
farm
appear
ideal
way
make
recombin
proteinbas
veterinari
vaccin
product
activ
ingredi
markedli
cheaper
per
unit
mass
use
anim
tissuecultur
system
gener
cheaper
yeast
bacteri
cultur
rybicki
partiallypurifi
unprocess
extract
highli
unlik
contain
anim
pathogen
edibl
oral
vaccin
appear
highli
feasibl
financi
barrier
entri
manufactur
appear
far
lower
conventionallymad
vaccin
possibl
effici
make
bacteri
protein
use
bacterialderiv
translat
machineri
chloroplast
transplastom
plant
well
make
protein
high
yield
convent
transgen
use
make
mani
vaccin
candid
mani
proof
efficaci
transient
express
technolog
revolutionis
field
term
provid
high
yield
rapid
develop
time
concept
product
yet
one
ndv
regist
use
sold
possibl
heavi
invest
big
industri
player
convent
manufactur
technolog
stall
uptak
molecular
farm
technolog
veterinari
vaccin
biolog
certainli
true
human
biolog
howev
perhap
develop
human
field
could
use
spur
uptak
veterinari
vaccin
biolog
exampl
licenc
protalix
biotherapeut
glucocerebrosidas
therapeut
genet
mitochondri
enzym
deficit
call
gaucher
diseas
made
use
transgen
carrot
cell
line
litr
plastic
bag
ferment
http
protalixcomaboutelelyso
contamin
genzym
mammalian
cell
product
facil
mammalian
caliciviru
led
fda
allow
protalix
suppli
drug
patient
need
acceler
licensur
bethencourt
compani
also
success
test
oral
administr
drug
plant
cell
would
highli
welcom
develop
claim
oral
deliveri
protein
therapi
possibl
due
uniqu
cellulos
wall
plant
cell
make
resist
degrad
pass
digest
tract
protalix
anoth
apposit
exampl
fortuit
avail
plantmad
antizair
ebolaviru
mab
cocktail
known
height
recent
west
african
ebola
diseas
outbreak
review
rybicki
made
transient
express
n
benthamiana
clinic
trial
dose
avail
use
humanitarian
principl
later
mab
clear
use
fda
efficaci
trial
end
epidem
leafbio
exampl
nich
product
made
larg
scale
larg
market
convent
techniqu
sudden
press
need
could
suppli
mean
could
provid
motiv
small
compani
either
develop
inexpens
vaccin
emerg
diseas
target
nich
vaccin
nich
therapeut
knowledg
larg
establish
entiti
unwil
take
risk
one
exampl
former
possibl
come
recent
emerg
bluetongu
viru
btv
diseas
sheep
small
rumin
europ
due
northward
spread
insect
vector
climat
chang
purs
et
al
attenu
live
vaccin
africa
present
use
cocktail
europ
reassort
viru
dsrna
genom
compon
vaccin
natur
diseas
anim
well
safeti
vaccin
term
possibl
underattenu
may
result
diseas
develop
certain
sheep
breed
niedbalski
mean
use
irregular
occurr
outbreak
limit
number
strain
involv
mean
stockpil
vaccin
desir
howev
kill
vaccin
still
requir
grow
potenti
danger
virus
possibl
make
vlp
cell
cultur
effect
pearson
roy
roy
et
al
technolog
expens
farm
anim
use
fortun
therefor
also
possibl
make
vlp
via
transient
express
n
benthamiana
effect
singl
inject
dose
commerci
vaccin
thuenemann
et
al
current
plan
manufactur
plantproduc
btv
vaccin
european
market
howev
may
soon
chang
exampl
nich
vaccin
product
come
other
work
beak
feather
diseas
viru
bfdv
vaccin
psittacin
highli
valu
companion
anim
howev
vaccin
diseas
none
yet
avail
bfdv
recent
work
area
shown
recombin
cp
made
e
coli
insect
cell
heath
et
al
patterson
et
al
stewart
et
al
appear
protect
bonn
et
al
appar
form
vlp
sarker
et
al
still
appear
protein
expens
produc
use
vaccin
initi
work
plant
product
bfdv
cp
disappoint
due
low
yield
recent
work
group
duvenag
et
al
show
signific
increas
bfdv
yield
due
fusion
elastinlik
polypeptid
elp
good
immunogen
mice
coupl
simpl
purif
protocol
enabl
elpyl
conley
et
al
could
allow
scalabl
cheap
product
bfdv
vaccin
therapeut
mab
biolog
veterinari
use
gener
limit
highvalu
companion
anim
plant
product
could
open
hitherto
neglect
market
nich
one
excel
exampl
manufactur
japan
canin
tabayashi
matsumura
done
via
transgen
strawberri
complet
enclos
gmpcompliant
facil
product
powder
strawberri
extract
given
oral
combat
canin
periodont
diseas
anoth
recent
exampl
dog
albeit
use
model
human
diseas
proof
lyophilis
transplastom
lettuc
leav
express
ctb
fusion
coagul
factor
ix
fix
could
use
oral
feed
day
haemophilia
b
dog
ill
treatment
result
robust
suppress
igginhibitor
ige
format
intravenouslyprovid
fix
mark
shorten
blood
coagul
time
herzog
et
al
exampl
agricultur
use
oral
dose
pig
transgen
arabidopsi
thaliana
seed
contain
design
iga
enterotoxigen
e
coli
etec
virdi
et
al
product
consist
dimer
llamaderiv
heavi
chain
variabl
region
fuse
fc
portion
porcin
iga
porcin
iga
j
chain
secretori
compon
allow
product
dimer
secretori
igalik
antibodi
vhhiga
piglet
feedchalleng
experi
etec
dose
piglet
mgd
per
pig
vhhiga
produc
progress
declin
bacteri
shed
significantli
higher
weight
gain
seen
control
experiment
pig
highli
novel
plantmad
therapeut
product
receptor
bind
domain
tailspik
protein
bacteriophag
known
reduc
salmonella
colonis
chicken
gut
milet
et
al
purifi
elpfus
bound
salmonella
enterica
serovar
typhimurium
vitro
feed
lyophil
leav
contain
newli
hatch
chicken
show
potenti
control
salmonella
contamin
commerciallyrais
fowl
experi
review
juarez
et
al
topp
et
al
articl
make
excel
case
plantmad
immunotherapeut
veterinari
use
one
health
concept
one
central
theme
integr
opportun
vaccinebas
approach
prevent
zoonot
emerg
diseas
across
veterinari
human
medicin
monath
three
differ
framework
use
vaccin
context
formul
framework
vaccin
use
protect
human
econom
valuabl
anim
neither
central
transmiss
cycl
good
exampl
would
west
nile
viru
mosquitoborn
flaviviru
spread
around
world
bird
incident
infect
anim
like
hors
well
human
framework
ii
vaccin
hand
intend
use
domest
anim
mean
prevent
diseas
anim
human
exampl
diseas
agent
would
brucella
aborti
e
coli
rabi
influenza
rift
valley
fever
hendra
virus
framework
iii
vaccin
immunis
nondomest
anim
order
prevent
transmiss
diseas
agent
human
domest
anim
exampl
use
oral
bait
rabi
mycobacterium
bovi
lyme
diseas
vaccin
set
diseas
agent
exemplifi
potenti
strength
one
health
approach
influenza
virus
fact
focu
number
intern
meet
plan
session
chien
dwyer
kirkland
kahn
et
al
ludwig
et
al
powdril
et
al
short
et
al
uniqu
mix
host
occur
intens
agricultur
environ
could
give
rise
bird
major
caus
intern
concern
develop
suitabl
vaccin
prevent
infect
domest
bird
farm
swine
human
plant
shown
highli
use
product
influenza
vaccin
inde
possibl
fastest
ever
product
scale
influenzaviru
strain
month
million
done
medicago
inc
ha
vlp
rybicki
medicago
also
manag
exercis
demonstr
prepared
produc
gram
cgmpgrade
plantmad
haonli
vlp
day
access
ha
gene
cdna
sequenc
respons
outbreak
china
year
fact
plantmad
influenza
vaccin
work
well
anim
model
mean
triall
extens
domest
fowl
swine
see
mainten
virus
host
curb
companion
anim
even
canin
influenza
vaccin
candid
follow
outbreak
us
group
canada
use
plantderiv
filament
malva
mosaic
viru
mamv
nanoparticl
vaccin
platform
display
highli
conserv
ectop
peptid
increas
immunogen
togeth
adjuv
ompc
deriv
salmonella
typhi
vaccin
protect
homolog
viru
heterosubtyp
strain
influenza
mice
well
elicit
antibodi
reactiv
peptid
deriv
strain
immunogen
dog
leclerc
et
al
given
brucellosi
list
one
health
prioriti
worth
note
transgen
plantproduc
b
abortu
outer
membran
protein
effect
oral
vaccin
mice
system
challeng
elicit
adapt
immun
respons
pasquevich
et
al
protein
signific
adjuv
activ
oral
vaccin
mice
plu
salmonella
antigen
protect
virul
challeng
typhimurium
risso
et
al
import
realis
vaccin
target
review
one
health
product
also
reagent
use
effect
cheaper
diagnost
kit
particular
pointofcar
devic
research
laboratori
especi
protein
could
reagent
use
candid
vaccin
anim
possibl
human
best
potenti
one
health
target
plantmad
dualfunct
protein
would
protein
middl
eastern
respiratori
syndrom
mer
coronaviru
wirblich
et
al
nipah
hendra
virus
landford
nunn
mackenzi
et
al
diagnosticvaccin
candid
protein
rift
valley
fever
crimeancongo
haemorrhag
fever
virus
kortekaa
monath
inexpens
abund
protein
made
agent
could
first
serv
reagent
develop
cheap
pointofcar
diagnost
vaccin
candid
anim
appropri
possibl
human
use
exampl
express
agroinfiltr
n
benthamiana
reagent
transgen
n
tabacum
root
leav
vaccin
fuse
gcgn
envelop
glycoproteinencod
gene
crimeancongo
haemorrhag
fever
viru
ghiasi
et
al
protein
yield
mgkg
fresh
plant
weight
transgen
materi
oral
immunogen
elicit
humor
mucos
antibodi
respons
antibodi
bound
inactiv
viru
use
vaccin
booster
experi
agroinfiltrationproduc
gngc
use
reagent
elisa
detect
immun
respons
anoth
studi
group
product
cchfv
n
protein
n
benthamiana
agroinfiltr
specif
reagent
use
diagnost
test
atkinson
et
al
plant
codonoptimis
tag
n
protein
gene
found
accumul
best
solubl
protein
cytoplasm
could
easili
purifi
ammonium
sulphat
fraction
immobilis
column
chromatographi
purifi
np
use
valid
indirect
elisa
detect
anticchfv
igg
sera
convalesc
human
patient
success
sampl
read
sampl
patient
histori
cchfv
infect
result
concord
commerci
avail
immunofluoresc
assay
given
solubl
n
protein
hard
produc
difficult
purifi
insect
cell
cultur
plantmad
product
would
seem
desir
replac
said
mani
venu
twenti
year
field
molecular
farm
realli
seem
near
meet
initi
promis
veterinari
use
technolog
requir
effici
highyield
product
biolog
place
downstream
process
modal
well
work
number
near
cgmpcompliant
facil
mani
candid
vaccin
wide
varieti
pathogen
test
therapeut
biolog
veterinari
use
feasibl
regulatori
agenc
seem
agreeabl
consid
plantmad
product
gener
shorter
regulatori
path
possibl
use
less
stringent
purifi
product
real
possibl
use
oral
vaccin
therapeut
also
highli
attract
product
develop
sincer
hope
realis
promis
come
soon
